Evolution of the Average Target: Spero Therapeutics, Inc.

Evolution of the Target Price: Spero Therapeutics, Inc.

Changes in Analyst Recommendations: Spero Therapeutics, Inc.

0.QJBNt6Zj-GFQaE5Y58NVY9EyAoiiibfOFC9noPCAT8g.BMR84ekbwAhgCyA5pJQPJuYGUNiS_9Gqf2UMxLezIq0swRXkkje5AghQBw~770fa2b578b9203a3bd4f8a87a24da13
21/10/25 Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr CI
20/12/24 Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5 MT
18/11/24 TD Cowen Downgrades Spero Therapeutics to Hold From Buy MT
06/08/24 TD Cowen Upgrades Spero Therapeutics to Buy From Hold MT
14/08/23 HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating MT
26/09/22 HC Wainwright Adjusts Spero Therapeutics' Price Target to $6 From $7, Maintains Buy Rating MT
23/09/22 Evercore ISI Upgrades Spero Therapeutics to Outperform From In-Line MT
15/08/22 HC Wainwright Adjusts Spero Therapeutics' Price Target to $7 From $10, Keeps Buy Rating MT
01/07/22 Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors MT
23/05/22 HC Wainwright Adjusts Spero Therapeutics' Price Target to $10 from $37, Keeps Buy Rating MT
20/05/22 Berenberg Bank Downgrades Spero Therapeutics to Hold From Buy, Adjusts Price Target to $2 From $44 MT
17/05/22 Cantor Fitzgerald Lowers Spero Therapeutics' Price Target to $5 From $27, Overweight Rating Kept MT
04/05/22 Cowen Downgrades Spero Therapeutics to Market Perform From Outperform MT
04/05/22 Evercore ISI Downgrades Spero Therapeutics to In-Line From Outperform, Adjusts Price Target to $2 From $40 MT
18/04/22 HC Wainwright Adjusts Spero Therapeutics' Price Target to $37 From $43, Maintains Buy Rating MT
21/03/22 HC Wainwright Adjusts Spero Therapeutics' Price Target to $43 From $40, Keeps Buy Rating MT
16/11/21 Berenberg Bank Adjusts Spero Therapeutics PT to $44 From $47, Maintains Buy Rating MT
01/10/21 Spero Therapeutics : Oppenheimer Downgrades Spero Therapeutics to Perform from Outperform MT
12/03/21 Spero Therapeutics : Oppenheimer Adjusts Spero Therapeutics PT to $20 From $21, Maintains Outperform Rating MT
22/01/21 Spero Therapeutics : HC Wainwright Adjusts Spero Therapeutics' Price Target to $40 From $33, Keeps at Buy MT
05/01/21 Spero Therapeutics : Oppenheimer Adjusts Spero Therapeutics PT to $21 From $19, Maintains Outperform Rating MT
16/12/20 Spero Therapeutics : Berenberg Starts Spero Therapeutics at Buy With $47 Price Target MT
23/11/20 Spero Therapeutics : HC Wainwright Adjusts Price Target on Spero Therapeutics to $33 From $28, Reiterates Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+19.65%
+16.26%
+60.29%
+20.86%
+17.06%
+13.34%
-0.55%
+26.73%
-6.91%
Average +18.52%
Weighted average by Cap. +19.95%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.170USD
Average target price
4.000USD
Spread / Average Target
+241.88%
High Price Target
4.000USD
Spread / Highest target
+241.88%
Low Price Target
4.000USD
Spread / Lowest Target
+241.88%

Analyst Consensus Detail

Consensus revision (last 18 months)

  1. Stock Market
  2. Stocks
  3. SPRO Stock
  4. 2HA Stock
  5. Consensus Spero Therapeutics, Inc.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!